Capricor Therapeutics’ (CAPR) Buy rating was reiterated at Maxim Group

Capricor Therapeutics (NASDAQ:CAPR – Get a Free Report)Its stock had a “buy” rating reiterated by research analysts at Maxim Group in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $12.00 target price on the biotechnology company’s stock. Maxim Group’s price objective indicates a potential upside of 134.38% from the stock’s current price.

Separately, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.00, based on data from MarketBeat.

Check out our latest research report on CAPR

Capricor Therapeutics trading rose 0.8%

Shares of NASDAQ CAPR opened at $5.12 on Tuesday. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $7.28. The company has a market cap of $163.73 million, a price-to-earnings ratio of -5.89 and a beta of 3.92. The stock’s 50-day simple moving average is $4.35 and its 200-day simple moving average is $5.18.

Capricor Therapeutics (NASDAQ:CAPR – Get Your Free Report ) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. As a group, equities analysts predict that Capricor Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional investors are weighing Capricor Therapeutics

Several institutional investors have recently bought and sold shares of CAPR. Vanguard Group Inc. raised its position in shares of Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after purchasing an additional 200,499 shares in the last quarter. Jump Financial LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $258,000. BNP Paribas Financial Markets purchased a new position in shares of Capricor Therapeutics in the 1st quarter valued at about $40,000. Main Street Financial Solutions LLC boosted its holdings in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after buying an additional 7,500 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Capricor Therapeutics in the second quarter valued at about $426,000. Institutional investors and hedge funds own 21.68% of the company’s shares.

Capricor Therapeutics Company Profile

(Get a free report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biologic therapies for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured stories

Receive daily news and ratings for Capricor Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Capricor Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.